Financial Survey: Carlyle Secured Lending (NASDAQ:CGBD) & Dominari (NASDAQ:DOMH)

Dominari (NASDAQ:DOMH) and Carlyle Secured Lending (NASDAQ:CGBD) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

42.5% of Dominari shares are held by institutional investors. Comparatively, 24.5% of Carlyle Secured Lending shares are held by institutional investors. 55.3% of Dominari shares are held by company insiders. Comparatively, 0.3% of Carlyle Secured Lending shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Dominari and Carlyle Secured Lending’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dominari	-51.61%	-235.37%	-163.66%
Carlyle Secured Lending	14.26%	8.85%	3.90%

Volatility & Risk

Dominari has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Carlyle Secured Lending has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Dominari and Carlyle Secured Lending, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1	0	0	0	1.00
Carlyle Secured Lending	0	4	3	0	2.43

Carlyle Secured Lending has a consensus price target of $12.50, suggesting a potential upside of 6.93%. Given Carlyle Secured Lending’s stronger consensus rating and higher probable upside, analysts plainly believe Carlyle Secured Lending is more favorable than Dominari.

Valuation & Earnings

This table compares Dominari and Carlyle Secured Lending”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$129.41 million	0.39	-$22.43 million	($5.39)	-0.39
Carlyle Secured Lending	$255.57 million	3.15	$69.97 million	$0.51	22.92

Carlyle Secured Lending has higher revenue and earnings than Dominari. Dominari is trading at a lower price-to-earnings ratio than Carlyle Secured Lending, indicating that it is currently the more affordable of the two stocks.

Summary

Carlyle Secured Lending beats Dominari on 11 of the 14 factors compared between the two stocks.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

About Carlyle Secured Lending

Carlyle Secured Lending, Inc. is business development company specializing in first lien debt, senior secured loans, second lien senior secured loan unsecured debt, mezzanine debt and investments in equities. It specializes in directly investing. It specializes in middle market. It targets healthcare and pharmaceutical, aerospace and defense, high tech industries, business services, software, beverage food and tobacco, hotel gamming and leisure, banking finance insurance and in real estate sector. The fund seeks to invest across United States of America, Luxembourg, Cayman Islands, Cyprus, and United Kingdom. It invests in companies with EBITDA between $25 million and $100 million.